https://www.linkedin.com/jobs/view/3691147705/
Program Lead - PSMA imaging and surgical assets
As the Program Lead you will be responsible for the successful early-stage development (preclinical to end of Phase 2 clinical trials) of Prostate-Specific Membrane Antigen (PSMA)-targeted imaging and surgical products. You will be responsible for working with the Global Senior Vice President of Clinical and Early-Stage Product Development to create, implement, manage and successfully execute product-specific global product development plans. The successful delivery of the product development plans will require leading and facilitating the cross-functional areas of manufacturing, non-clinical, clinical and regulatory.
This role is critical to the further development and successful delivery of Telix's product portfolio by driving the current and future development of the PSMA-targeted imaging and surgical product lines.
What You'll Do
- Work as part of a cross-functional team to create product development and commercialisation plans for Telix PSMA-targeted imaging and surgical products.
- Lead a cross-functional team to deliver the program and product development milestones up to the end of Phase 2 clinical evaluation.
- Manage and lead Project Manager to apply project management best practice, with the objective of progressing the Telix product portfolio through development within project timelines and budget.
- Complete oversight of the successful delivery of product development plans and product approvals, more specifically:
- Maintenance of up-to-date documentation of product positioning and target product profile.
- Progress tracking of all activities against the development plan and notification of potential delays and/or other changes.
- Documentation and tracking of the Program budget; working with Finance and the project manager to ensure contracts and costs are recorded in an accurate and timely manner.
- Work with senior management to assess product development risks and compile risk mitigation and scenario plans for Telix PSMA-targeted imaging and surgical products.
- Ensuring all Program Team members and the Executive are kept informed of project status, costs and risks.
- Maintaining current awareness of Program-related scientific, clinical and commercial functional knowledge.
- Forums
- ASX - By Stock
- TLX
- Ann: Lightpoint Acquisition to Expand Telix Urologic Pipeline
Ann: Lightpoint Acquisition to Expand Telix Urologic Pipeline, page-21
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$22.20 |
Change
0.750(3.50%) |
Mkt cap ! $7.429B |
Open | High | Low | Value | Volume |
$21.90 | $22.27 | $21.77 | $48.54M | 2.197M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 13813 | $22.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$22.21 | 1656 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 13813 | 22.150 |
1 | 4057 | 22.060 |
2 | 4080 | 22.020 |
4 | 783 | 22.000 |
1 | 4057 | 21.990 |
Price($) | Vol. | No. |
---|---|---|
22.210 | 1656 | 2 |
22.260 | 4057 | 1 |
22.280 | 1430 | 2 |
22.300 | 6157 | 6 |
22.330 | 4057 | 1 |
Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |